Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Pfizer will support Riparian's efforts to discover further drug targets leading to vasoprotection and will have an option on such targets for cardiovascular diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Riparian Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 20, 2023
Details:
Under the terms of the collaboration, Schrödinger will identify drug discovery targets for which there are currently no crystal structures in the public domain, including those that could lead to first-in-class therapeutic candidates for its internal pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Schrodinger
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 28, 2020